Table 2.
Baseline characteristics and clinical characteristics after intravenous thrombolysis in AIS patients.
| Male (n = 639) | Female (n = 314) | |||||
|---|---|---|---|---|---|---|
| mRS 0–1 (n = 463) | mRS ≥2 (n = 176) | P value | mRS 0–1 (n = 206) | mRS ≥2 (n = 108) | P value | |
| Age, y (IQR) | 62 (53–70) | 65 (56–73) | 0.002 | 66 (56–77) | 74 (66–81) | <0.001 |
| Smoking history, n (%) | 211 (45.6) | 90 (51.1) | 0.208 | 11 (5.3) | 7 (6.5) | 0.679 |
| Drinking history, n (%) | 190 (41) | 52 (29.5) | 0.007 | 1 (0.5) | 1 (0.9) | 0.641 |
| Previous stroke, n (%) | 83 (17.9) | 35 (19.9) | 0.568 | 31 (15) | 26 (24.1) | 0.049 |
| Hypertension, n (%) | 245 (52.9) | 104 (59.1) | 0.161 | 130 (63.1) | 68 (63) | 0.980 |
| Diabetes mellitus, n (%) | 71 (15.3) | 27 (15.3) | 0.998 | 42 (20.4) | 29 (26.9) | 0.193 |
| Coronary artery disease, n (%) | 62 (13.4) | 26 (14.8) | 0.651 | 40 (19.4) | 26 (24.1) | 0.366 |
| Atrial fibrillation, n (%) | 22 (4.8) | 18 (10.2) | 0.011 | 30 (14.6) | 30 (27.8) | 0.005 |
| Body mass index, kg/m2 (IQR) | 24.2 (22.5–26.3) | 23.7 (21.5–25.95) | 0.018 | 23.4 (21–26.7) | 22.85 (20.3–25.85) | 0.151 |
| Heart rate, bpm (IQR) | 76 (70–84) | 76 (68–86) | 0.771 | 76 (69–85) | 80 (71–91) | 0.029 |
| Systolic blood pressure, mmHg (IQR) | 150 (136–166) | 153 (138–168) | 0.361 | 150 (136–167) | 160 (142–177) | 0.016 |
| Diastolic blood pressure, mmHg (IQR) | 90 (80–100) | 90 (80–99) | 0.906 | 85 (78–95) | 89 (80–98) | 0.098 |
| TOAST, n (%) | <0.001 | <0.001 | ||||
| Large artery atherosclerosis | 204 (44.1) | 104 (59.1) | 85 (41.5) | 56 (51.9) | ||
| Cardioembolism | 39 (8.4) | 22 (12.5) | 26 (12.7) | 37 (34.3) | ||
| Small artery occlusion | 180 (38.9) | 37 (21) | 75 (36.6) | 12 (11.1) | ||
| Other determined | 10 (2.2) | 5 (2.8) | 3 (1.5) | 1 (0.9) | ||
| Undetermined | 30 (6.5) | 8 (4.5) | 16 (7.8) | 2 (1.9) | ||
| Median NIHSS on admission | 5 (3–7) | 10 (5–15) | <0.001 | 5 (3–9) | 12 (9–17) | <0.001 |
| Onset-to-needle time, m (IQR) | 175 (130–213) | 165 (122–208) | 0.348 | 165 (125–200) | 174 (145–215) | 0.114 |
| Random blood sugar, mmol/L (IQR) | 6.55 (5.62–8.05) | 6.8 (6.0–8.9) | 0.029 | 6.9 (5.8–8.61) | 7.44 (6.2–10.1) | 0.026 |
| White blood cell, ⅹ10^9/L (IQR) | 7.47 (6.1–9.2) | 7.91 (6.45–9.99) | 0.057 | 7.07 (5.7–8.79) | 7.2 (5.96–9.40) | 0.220 |
| Hemoglobin, g/L (IQR) | 148 (137–158) | 144 (132–154) | 0.003 | 130 (123–139) | 131 (122–141) | 0.843 |
| Albumin, mg/L (IQR) | 40 (36.5–42.4) | 38.25 (35.33–41.96) | 0.006 | 38.85 (35.48–41.7) | 38.55 (35.68–42.2) | 0.887 |
| Blood urea nitrogen, mmol/L (IQR) | 5.48 (4.5–6.55) | 5.7 (4.68–7.06) | 0.057 | 5.27 (4.39–6.35) | 5.82 (4.95–7.1) | 0.002 |
| Creatinine, μmol/L (IQR) | 72.3 (63–85) | 74 (62.63–90.98) | 0.116 | 58 (48–69) | 63 (52–73) | 0.036 |
| Urate, μmol/L (IQR) | 319 (247.8–394) | 300.5 (227.5–385) | 0.349 | 264.8 (201.75–340.88) | 252.2 (191.68–334.7) | 0.354 |
AIS, acute ischemic stroke; IQR, interquartile range; TOAST, trial of org 10,172 in acute stroke treatment; NIHSS, national institute of health stroke scale; mRS, modified Rankin scale.